TB-500 Side Effects: Human Evidence and Safety Gaps
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
There is no single reliable side-effect rate that applies to every product called TB-500. The name can refer to different peptide materials, and the human studies frequently cited online do not all test the same molecule. A short study of a defined research medicine also cannot establish the safety of an unrelated vial.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted article is not an independent scientific review. Source-access limits appear below.

Why the name matters for TB-500 side effects
FDA's May 2026 review, prepared for its July advisory meeting, evaluated a seven-amino-acid fragment, Ac-LKKTETQ, and its acetate form. It highlighted inconsistent naming, uncertainty about product composition and potential immune-response concerns related to aggregation or impurities. Those concerns are different from measured rates of confirmed adverse reactions. FDA briefing.
Natural thymosin beta-4 is a larger, 43-residue peptide. One recombinant clinical candidate is different again. Before borrowing a safety claim, match the exact sequence and formulation to the publication. Our TB-500 identity guide explains that distinction.
What the human studies actually observed
Study | Material and participants | Reported safety finding | Boundary |
|---|---|---|---|
Ruff, 2010 | Synthetic thymosin beta-4; 40 healthy volunteers in an intravenous study | Events were infrequent and mild or moderate; no serious events or dose-limiting toxicity reported | Short controlled exposure, including a 14-day repeat-exposure phase; not proof about a seven-residue fragment |
Wang, 2021 | NL005, a 44-residue recombinant construct; separate cohorts of 54 and 30 healthy adults | Mild/moderate events occurred in active and placebo groups; no serious events or dose-limiting toxicity reported | Follow-up lasted 28 days; the construct and setting differ from a commercial research vial |
Sources: Ruff study abstract, Wang full study.
In the 2021 single-exposure cohort, adverse events were recorded in 25 of 44 active-treatment participants and 7 of 10 placebo participants. That does not mean each event was caused by the peptide, or that the active treatment was safer than placebo. The sample and observation period limit both conclusions. An adverse event is an observation; establishing a causal side effect requires additional assessment.
Why missing reports do not mean zero risk
A meaningful safety estimate needs the number of exposed participants, how events were sought, a comparison group and adequate follow-up. Testimonials and an unspecified number of uneventful experiences cannot supply those denominators.
The dated FDA briefing did not identify qualifying clinical safety studies for the fragment it evaluated. Its reporting-system discussion also warned that absent or incomplete reports could not establish safety. This should not be rewritten as “no human has ever been exposed.” Subsequent policy documents describe additional historical use.
Does the 2026 policy change prove safety?
No. The October 30 Federal Register notice announced an interim compounding enforcement policy. The HHS policy includes conditions concerning exact identity, testing, single-ingredient products and reporting. It expressly distinguishes compounded drugs from FDA-approved drugs.
That policy is not a clinical trial and does not certify a research catalog vial. A policy change, evidence of historical use and a controlled safety study answer different questions.
Common safety questions
Are TB-500 side effects usually mild?
The mild/moderate findings above describe particular thymosin beta-4 study products. They do not establish what is usual across materials sold under the TB-500 name.
Does a high-purity COA make TB-500 safe?
A certificate can document specific analytical results for the tested sample. It does not establish clinical safety, and a purity result alone does not answer every identity or contamination question. See our COA methods guide.
Is combining BPC-157 and TB-500 proven safe?
The studies summarized here do not establish combination safety. The BPC-157/TB-500 stack evidence guide discusses why findings about one material cannot automatically validate a combination.
Review method and source access
This focused review checked the 2021 publisher full text, the 2010 publisher abstract, the dated FDA briefing and the October HHS policy documents on November 18, 2026. The two study abstracts were rechecked on November 19, 2026; the 2021 full paper, FDA briefing and HHS policy were not re-accessed during that recheck. It is not a systematic review or independent scientific peer review. Bio Peptides Labs catalog materials remain for lawful laboratory research, not human or veterinary use.
References
These are the sources discussed above. Access scope and review limits are stated in the review-method section.
